These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 17065015

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Disease transformation in imatinib mesylate treated Philadelphia chromosome-positive chronic myelogenous leukemia patients achieved cytogenetic remissions].
    Jiang Q, Chen SS, Jiang B, Jiang H, Lu Y, Lu DP.
    Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Dec 18; 37(6):612-5. PubMed ID: 16378113
    [Abstract] [Full Text] [Related]

  • 4. Prognostic factors associated with complete cytogenetic response in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
    Cojbasić I, Macukanović-Golubović L.
    Srp Arh Celok Lek; 2010 Dec 18; 138(5-6):305-8. PubMed ID: 20607973
    [Abstract] [Full Text] [Related]

  • 5. Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy.
    Rytting ME, Wierda WG.
    Leuk Lymphoma; 2004 Aug 18; 45(8):1623-6. PubMed ID: 15370215
    [Abstract] [Full Text] [Related]

  • 6. Is telomerase a player in chronic phase chronic myeloid leukemia, disease progression and imatinib resistance?
    White DL.
    Leuk Lymphoma; 2008 Jun 18; 49(6):1022-3. PubMed ID: 18452091
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
    Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S, Thomas DA, Garcia-Manero G, Issa JP, Andreeff M, Kornblau SM, Koller C, Beran M, Keating M, Rios MB, Shan J, Resta D, Capdeville R, Hayes K, Albitar M, Freireich EJ, Cortes JE.
    Clin Cancer Res; 2002 Jul 18; 8(7):2177-87. PubMed ID: 12114418
    [Abstract] [Full Text] [Related]

  • 10. Imatinib mesylate in the treatment of chronic myelogenous leukemia.
    Borthakur G, Cortes JE.
    Int J Hematol; 2004 Jun 18; 79(5):411-9. PubMed ID: 15239390
    [Abstract] [Full Text] [Related]

  • 11. Chronic myeloid leukemia presenting with extramedullary disease as massive ascites responding to imatinib mesylate.
    Aleem A, Siddiqui N.
    Leuk Lymphoma; 2005 Jul 18; 46(7):1097-9. PubMed ID: 16019565
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Treatment of chronic myeloid leukemia with imatinib in the accelerated stage of the disease].
    Bulum J, Labar B, Mikulić M, Bogdanić V, Sertić D, Nemet D, Krecak-Gverić V, Kovacević J, Serventi-Seiwerth R, Mrsić-Davidović S, Zadro R, Boban D.
    Lijec Vjesn; 2003 Jul 18; 125(7-8):176-9. PubMed ID: 14692090
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy.
    Kantarjian HM, Bueso-Ramos CE, Talpaz M, O'Brien S, Giles F, Rios MB, Shan J, Cortes J.
    Leuk Lymphoma; 2005 Jul 18; 46(7):993-7. PubMed ID: 16019549
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.